Manipulation of hepatic blood flow may improse drug delivery to hepatic tumour. Somatostatin and its long acting analogues are known to elicit effects upon hepatic and splanchnic blood flow in experimental animals and patients with portal hypertension. This study investigates the effects of SMS 201-995 (sandostatin) infusion on hepatic. splanchnic and tumour blood flow in an experimental model of liver metastases.
Up to 600o of patients with colorectal cancer develop liser metastases which are rarely surgically resectable (Finlav et al.. 1982) and systemic or regional chemotherapy is often used to treat these patients (Kemeney et al.. 1987) . The extraction of regionally delivered drug by the liver is inversely proportional to hepatic blood flow (Sigurdson et al.. 1986) and as many hepatic tumours are hypovascular this may limit delivery of the chemotherapeutic drug to tumour and may. in part. explain the relatively poor response rates to chemotherapy Manipulation of hepatic blood flow by vasoactiye agents may therefore improve extraction of drug by the liver. In addition, an alteration in the relative blood flow distribution between the normal liver parenchyma and hepatic tumour may also improve drug delivery to hepatic tumour.
Somatostatin and its long acting analogue sandostatin . are known to elicit effects upon hepatic and splanchnic blood flow in experimental animals and patients with cirrhosis and portal hypertension (Keller et al.. 1978 : Price et al.. 1985 : Sonnenbert et al.. 1981 (Hemingway et al.. 1991b (Table I) . but hepatosplanchnic flow did fall significantly (P = 0.032) from 9.7(8.77) ml min-' to 7.0 (1.99) ml min' after SMS infusion (Table I) . Tumour blood flow was reduced from 0.28(0.18) ml min-' g-1 to 0.10(0.08) although the reduction was not statistically significant. In contrast. blood flow to normal hepatic parenchvma was significantly reduced (P = 0.014) from 0.37(0.28) ml minm g-I to 0.16(0.09) ml min-' g'. The tumour:liver blood flow ratio was significantly increased (P = 0.042) from 0.55(0.47) to 0.75(0.62) ( Table I) .
Discusion
We have previously demonstrated that there are significant alterations in liver blood flow in the presence of hepatic tumour (Hemingway et al.. 1991b (Keller et al.. 1978) . Similarly. studies in dogs have demonstrated that somatostatin infusion reduces portal venous inflow by up to 30% (Price et al.. 1985) . Vasoactive agents can have profound effects upon hepatic blood flow in man and animals with hepatic tumour (Hemingway et al.. 1991c : Sasaki et al.. 1985 . This is confirmed in this study which clearly demonstrates a significant reduction in both hepatic arterial flow and results in a decrease in total hepatosplanchnic flow when SMS 201-995 was infused. The reduction in hepatic arterial flow was associated with a rise in the tumour:liver blood flow ratio which was due predominantly to a fall in the arterial supply to the surrounding normal hepatic parenchyma. with no significant change in the measured tumour blood flow. This confirms the observations of Mattson et al. (1977) who reported that the blood vessels of tumours were immature. lacking muscular or nervous elements. and thus unable to respond to vasoactive agents. The first of each pair of values is the pre-infusion value and the second is the post-infusion value.
Hepatic arterial vasoconstriction takes place predominantly in the blood vessels of the normal hepatic parenchyma leading to an increase in the relative blood flow to hepatic tumour. This may be of clinical value as it may lead to preferential delivery of concomitantly administered cytotoxic agents to tumours with relative sparing of normal hepatic parenchyma.
In previous studies we have observed that SMS 201-995 inhibits the growth of hepatic tumour derived from the intraportal inoculation of Walker carcinosarcoma cells which was associated with a marked stimulation of the reticuloendothelial system (Nott et al.. 1989) . Since the RES comprises the bodv s natural defence system against tumour cells. it was suggested that the stimulation of the Kuppfer cells may have been in part responsible for the inhibition of growth of the hepatic tumour. Although comparisons of liver blood flow were made between the two groups in that study. firm conclusions could not be made regarding the effect of SMS 201-995 on liver blood flow and its effect on tumour growth since there was very little tumour in the liver in the group treated with sandostatin at the end of the 3 week period. The results of this study however suggest that SMS 201-995. by reducing hepatic arterial flow may well influence the growth of hepatic tumour which derives its nutritive blood supply almost entirely from the hepatic artery.
